CX717

Last updated
CX717
CX717.svg
Clinical data
Routes of
administration
By mouth, IV
ATC code
  • None
Identifiers
  • 5-(Morpholine-4-carbonyl)-2,1,3-benzoxadiazole [1] [2]
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C11H11N3O3
Molar mass 233.227 g·mol−1
3D model (JSmol)
  • C1COCCN1C(=O)C2=CC3=NON=C3C=C2
  • InChI=1S/C11H11N3O3/c15-11(14-3-5-16-6-4-14)8-1-2-9-10(7-8)13-17-12-9/h1-2,7H,3-6H2
  • Key:KFRQROSRKSVROW-UHFFFAOYSA-N
 X mark.svgNYes check.svgY  (what is this?)

CX717 is an ampakine compound created by Christopher Marrs and Gary Rogers in 1996 [3] at Cortex Pharmaceuticals. It affects the neurotransmitter glutamate, with trials showing the drug improves cognitive functioning and memory. [4]

Contents

Approval process

In 2005 the U.S. Food and Drug Administration (FDA) accepted Cortex Pharmaceuticals' Investigational New Drug (IND) application to initiate pilot Phase II clinical trials in the United States.

Also, in 2005, the United States Department of Defense funded a study to look into CX717 and the physiological effects of sleepiness. The study found that rhesus monkeys performed faster and better after receiving the drug, and it counteracted the effects of sleep deprivation. [5] [4]

However, a 2006 study funded by DARPA found that CX717 did not improve cognitive performance in humans subjected to simulated night shift work. [6]

In early March 2006 Cortex reported that, in a small pilot Phase II study, CX717 had demonstrated positive clinical and statistical results on the primary endpoint, the ADHD rating scale and the sub-scales related to attention and hyperactivity which are used for the approval of all currently available ADHD treatments. According to a Cortex Pharmaceuticals press release, "Consistent with all previous studies involving over 220 patients and healthy adults, this study demonstrated that CX717 was safe, well tolerated, and produced no increase in heart rate, blood pressure or other cardiovascular side effects".

In April 2007 Cortex Pharmaceuticals submitted two large data packages to the FDA regarding CX717. One data set went to the FDA's Division of Neurology Drug Products for the treatment of Alzheimer's disease, while the other went to the Division of Psychiatry Products where the company filed a second CX717 IND for the treatment of ADHD. According to a Cortex Pharmaceuticals press release, the submitted data package "provides clear evidence that the specific histopathological changes seen in animal toxicology studies, which previously caused the FDA to put CX717 on clinical hold, is a postmortem fixation artifact and is not found in the tissue of the animal when it is still living". [7]

Roger G Stoll PhD, chief executive officer of Cortex, stated,

“When CX717 was removed from clinical hold on October 6, 2006 by the Neurology Division a dose was permitted for continuing a study in patients with Alzheimer's disease, but that dose was too low to permit the assessment of the drug in patients with ADHD. Further information was needed to better understand the cause of the histopathological changes. We now have a substantial data base which clearly documents the fact that the histological changes of concern occur postmortem when the fixative solution is used to prepare the slides of the tissue specimens.”

However, in October 2007 the FDA denied Cortex's IND application for a Phase IIb study of CX717 for treatment of ADHD, based on the same animal toxicology results. Cortex responded by inactivating the application, although it will "continue its plans to develop CX717 for the acute treatment of respiratory depression (RD) and continue its study of CX717 in its Alzheimer’s disease PET scan study. Cortex believes that the IND application previously filed with the Division of Neurology Products of the FDA for the treatment of Alzheimer’s disease will not be affected by the actions of the DPP." [8] The company hopes that after the use of the compound in treating a high-risk acute condition is approved and well-established, the risks of longer-term use at higher doses, such as for treatment of ADHD, will be shown to be less than the FDA had concluded.

Use for reversal of respiratory depression

The relatively poor oral bioavailability and blood–brain barrier penetration of CX-717 ultimately led to Cortex abandoning development of the 800 mg oral formulation of CX-717 for ADHD, [9] although research into its action in the brain continues. [4] However the unexpected discovery of the strong respiratory stimulant effects of the ampakine drugs on the pre-Botzinger complex of the brain has led to continued development of an intravenous formulation of CX-717 for use alongside opioid analgesics, [10] along with an oral formulation of CX-1739, which is around 3-5× more potent than CX-717 and has better oral bioavailability, and is being trialled for treatment of sleep apnea. [11] Further research has investigated the neurological mechanisms behind the anti-respiratory depressant effects of CX-717, [12] and demonstrated that it can be used in humans alongside opioid drugs to reduce this side effect without affecting analgesia. [13]

Other AMPAkine drugs from Cortex Pharmaceuticals such as CX-546 and CX-614 have already been researched for use in treating Alzheimer's disease and ADHD. These drugs were reasonably effective at reducing the symptoms of Alzheimer's and it was hoped that they could also slow the progression of the disease, but both CX-546 and CX-614 have poor bioavailability, and are only active at very high doses of 1000 mg or more. CX-717 and CX-1739 are newer and more potent drugs in the same series. [14] [15] [16]

See also

Related Research Articles

<span class="mw-page-title-main">Atomoxetine</span> Medication used to treat ADHD

Atomoxetine, sold under the brand name Strattera, is a medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome. It may be used alone or along with psychostimulants. It is also used as a cognitive and executive functioning enhancer to improve self-motivation, persistence, attention, inhibition, and working memory. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. Atomoxetine is a selective norepinephrine reuptake inhibitor and is believed to work by increasing norepinephrine and dopamine levels in the brain.

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

<span class="mw-page-title-main">Diazoxide</span> Medication used to treat low blood sugar and high blood pressure

Diazoxide, sold under the brand name Proglycem and others, is a medication used to treat low blood sugar due to a number of specific causes. This includes islet cell tumors that cannot be removed and leucine sensitivity. It can also be used in refractory cases of sulfonylurea toxicity. It is generally taken by mouth.

<span class="mw-page-title-main">Ampakine</span> Subgroup of AMPA receptor positive allosteric modulators

Ampakines or AMPAkines are a subgroup of AMPA receptor positive allosteric modulators with a benzamide or closely related chemical structure. They are also known as "CX compounds". Ampakines take their name from the AMPA receptor (AMPAR), a type of ionotropic glutamate receptor with which the ampakines interact and act as positive allosteric modulators (PAMs) of. Although all ampakines are AMPAR PAMs, not all AMPAR PAMs are ampakines.

<span class="mw-page-title-main">Analeptic</span> Drug class

An analeptic, in medicine, is a central nervous system stimulant. The term "analeptic" typically refers to respiratory analeptics. Analeptics are central nervous system (CNS) stimulants that include a wide variety of medications used to treat depression, attention deficit hyperactivity disorder (ADHD), and respiratory depression. Analeptics can also be used as convulsants, with low doses causing patients to experience heightened awareness, restlessness, and rapid breathing. The primary medical use of these drugs is as an anesthetic recovery tool or to treat emergency respiratory depression. Other drugs of this category are prethcamide, pentylenetetrazole, and nikethamide. Nikethamide is now withdrawn due to risk of convulsions. Analeptics have recently been used to better understand the treatment of a barbiturate overdose. Through the use of agents, researchers were able to treat obtundation and respiratory depression.

<span class="mw-page-title-main">CX-516</span> Chemical compound

CX-516 is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator and had been undergoing development by a collaboration between Cortex, Shire, and Servier. It was studied as a potential treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD.

<span class="mw-page-title-main">Farampator</span> Chemical compound

Farampator is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator was transferred. The development of farampator was eventually terminated, reportedly due to concerns about cardiac toxicity.

<span class="mw-page-title-main">CX614</span> Chemical compound

CX-614 is an ampakine drug developed by Cortex Pharmaceuticals. It has been investigated for its effect on AMPA receptors.

<span class="mw-page-title-main">CX-546</span> Chemical compound

CX-546 is an ampakine drug developed by Cortex Pharmaceuticals.

<span class="mw-page-title-main">IDRA-21</span> Chemical compound

IDRA-21 is a positive allosteric modulator of the AMPA receptor and a benzothiadiazine derivative. It is a chiral molecule, with (+)-IDRA-21 being the active form.

<span class="mw-page-title-main">LY-503430</span> Chemical compound

LY-503430 is an AMPA receptor positive allosteric modulator developed by Eli Lilly.

<span class="mw-page-title-main">Tebanicline</span> Chemical compound

Tebanicline is a potent synthetic nicotinic (non-opioid) analgesic drug developed by Abbott. It was developed as a less toxic analog of the potent poison dart frog-derived compound epibatidine, which is about 200 times stronger than morphine as an analgesic, but produces extremely dangerous toxic side effects. Like epibatidine, tebanicline showed potent analgesic activity against neuropathic pain in both animal and human trials, but with far less toxicity than its parent compound. It acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.

RespireRx Pharmaceuticals Inc. is a pharmaceutical company based in Glen Rock, New Jersey specializing in positive allosteric modulators of the AMPA receptor known as Ampakines.

<span class="mw-page-title-main">LY-404187</span> Chemical compound

LY-404187 is an AMPA receptor positive allosteric modulator which was developed by Eli Lilly and Company. It is a member of the biarylpropylsulfonamide class of AMPA receptor potentiators.

<span class="mw-page-title-main">ORG-26576</span> Ampakine

ORG-26576 is an ampakine originally developed by Cortex Pharmaceuticals and then licensed to Organon International for development. In animal studies it has been shown to effectively potentiate AMPA receptor function, leading to increased BDNF release and enhanced neuronal differentiation and survival, as well as producing nootropic effects in standardised assays. Development as an antidepressant has been halted due to a failed Phase II trial for major depressive disorder.

<span class="mw-page-title-main">Pesampator</span> Chemical compound

Pesampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by Pfizer for the treatment of cognitive symptoms in schizophrenia. It was also under development for the treatment of age-related sensorineural hearing loss, but development for this indication was terminated due to insufficient effectiveness. As of July 2018, pesampator is in phase II clinical trials for cognitive symptoms in schizophrenia.

<span class="mw-page-title-main">Mibampator</span> Chemical compound

Mibampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which was under development by Eli Lilly for the treatment of agitation/aggression in Alzheimer's disease but was never marketed. It reached phase II clinical trials prior to the discontinuation of its development.

<span class="mw-page-title-main">Tulrampator</span> Chemical compound

Tulrampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which is under development by RespireRx Pharmaceuticals and Servier for the treatment of major depressive disorder, Alzheimer's disease, dementia, and mild cognitive impairment. Tulrampator was in phase II clinical trial for depression, but failed to show superiority over placebo. There are also phase II clinical trials for Alzheimer's disease and phase I trials for dementia and mild cognitive impairment.

<span class="mw-page-title-main">AMPA receptor positive allosteric modulator</span>

AMPA receptor positive allosteric modulators are positive allosteric modulators (PAMs) of the AMPA receptor (AMPR), a type of ionotropic glutamate receptor which mediates most fast synaptic neurotransmission in the central nervous system.

References

  1. Radin DP, Purcell R, Lippa AS (January 2018). "Oncolytic Properties of Ampakines In Vitro". Anticancer Research. 38 (1): 265–269. doi: 10.21873/anticanres.12217 . PMID   29277782.
  2. Purcell R, Lynch G, Gall C, Johnson S, Sheng Z, Stephen MR, et al. (April 2018). "Brain Vacuolation Resulting From Administration of the Type II Ampakine CX717 Is An Artifact Related to Molecular Structure and Chemical Reaction With Tissue Fixative Agents". Toxicological Sciences. 162 (2): 383–395. doi: 10.1093/toxsci/kfx277 . PMID   29253237.
  3. US 6110935,Rogers GA, Marrs CM,"Benzofurazan compounds for enhancing glutamatergic synaptic responses",issued 29 August 2000, assigned to University of California.
  4. 1 2 3 Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA (January 2009). "Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717". Psychopharmacology. 202 (1–3): 355–369. doi:10.1007/s00213-008-1360-z. PMC   3107999 . PMID   18985324.
  5. Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA (September 2005). "Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates". PLOS Biology. 3 (9): e299. doi:10.1371/journal.pbio.0030299. PMC   1188239 . PMID   16104830.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. "Top-line findings on CX717 from the DARPA-sponsored shift work simulation study will be presented at sleep 2006 meeting". Cortex News & Events. Archived from the original on 2007-09-27. Retrieved 2007-10-21.
  7. "Cortex's AMPAKINE CX-717 Toxicology Data Package Submitted to FDA". Archived from the original on 2009-01-06. Retrieved 2009-03-31.
  8. "FDA's Psychiatric Division has Rejected Cortex's Request to Study CX717 in Phase IIb ADHD Study" . Retrieved 2008-02-28.
  9. "Untitled Document". Archived from the original on 2009-04-06. Retrieved 2009-07-20.
  10. Ren J, Ding X, Funk GD, Greer JJ (June 2009). "Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats". Anesthesiology. 110 (6): 1364–1370. doi: 10.1097/ALN.0b013e31819faa2a . PMID   19461299.
  11. "Cortex Annual Shareholder Meeting Notification". Cortex Pharmaceuticals Press. 1 June 2009. Archived from the original on 23 February 2009. Retrieved 20 July 2009.
  12. Lorier AR, Funk GD, Greer JJ (January 2010). Hochman S (ed.). "Opiate-induced suppression of rat hypoglossal motoneuron activity and its reversal by ampakine therapy". PLOS ONE. 5 (1): e8766. Bibcode:2010PLoSO...5.8766L. doi: 10.1371/journal.pone.0008766 . PMC   2808240 . PMID   20098731.
  13. Oertel BG, Felden L, Tran PV, Bradshaw MH, Angst MS, Schmidt H, et al. (February 2010). "Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia". Clinical Pharmacology and Therapeutics. 87 (2): 204–211. doi:10.1038/clpt.2009.194. PMID   19907420. S2CID   10723185.
  14. Mueller R, Li YX, Hampson A, Zhong S, Harris C, Marrs C, et al. (July 2011). "Benzoxazinones as potent positive allosteric AMPA receptor modulators: part I". Bioorganic & Medicinal Chemistry Letters. 21 (13): 3923–3926. doi:10.1016/j.bmcl.2011.05.026. PMID   21636275.
  15. Mueller R, Rachwal S, Tedder ME, Li YX, Zhong S, Hampson A, et al. (July 2011). "Substituted benzoxazinones as potent positive allosteric AMPA receptor modulators: part II". Bioorganic & Medicinal Chemistry Letters. 21 (13): 3927–3930. doi:10.1016/j.bmcl.2011.05.024. PMID   21636273.
  16. Mueller R, Rachwal S, Lee S, Zhong S, Li YX, Haroldsen P, et al. (October 2011). "Benzotriazinone and benzopyrimidinone derivatives as potent positive allosteric AMPA receptor modulators". Bioorganic & Medicinal Chemistry Letters. 21 (20): 6170–6175. doi:10.1016/j.bmcl.2011.07.098. PMID   21889339.

Further reading